FAP 靶向 PET/CT 用于无创监测肾纤维化
Chronic kidney disease (CKD) is an irreversible change of kidney function and structure caused by many reasons. The main threat of CKD to human health is progressive renal function decline. Delaying the progression of chronic kidney disease to end-stage renal failure is an important clinical need, and renal fibrosis is a common pathway for the progression of chronic kidney disease to end-stage renal failure. The evaluation of renal fibrosis is of great value for the course and prognosis of patients with chronic kidney disease. However, pathological detection has the disadvantages of trauma, false negative, and cannot be implemented repeatedly. At present, there is a lack of effective non-invasive, dynamic, real-time monitoring and evaluation means. A commercially available FAP-targeted imaging agent, FAPI-04, has been used for PET/CT imaging of systemic fibrosis lesions with high uptake background in normal kidneys. Although it can show severe renal fibrosis, it is not conducive to the detection rate of patients with mild-moderate fibrosis who need more accurate evaluation. The new targeted FAP imaging agent successfully constructed by our research group has proved that it can show the degree of renal fibrosis at the living level and has correlation. Therefore, this study intends to carry out a series of clinical studies on the imaging of renal fibrosis with new targeted FAP probes, evaluate the specificity and sensitivity of the new targeted FAP probes in the diagnosis of renal fibrosis, and ultimately provide a new method for clinical dynamic, non-invasive assessment and monitoring of the degree and progression of renal fibrosis.
研究概览
地位
研究类型
注册 (估计的)
阶段
- 不适用
联系人和位置
学习地点
-
-
Beijing Municipality
-
Beijing、Beijing Municipality、中国
- Peking University First Hospital
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Patients with chronic kidney disease
- Renal pathology was performed within 2 weeks
Exclusion Criteria:
- Pregnant or lactating patients
学习计划
研究是如何设计的?
设计细节
- 主要用途:诊断
- 分配:不适用
- 介入模型:单组作业
- 屏蔽:无(打开标签)
武器和干预
参与者组/臂 |
干预/治疗 |
|---|---|
|
实验性的:FAP-targeting PET/CT imaging
FAP-targeting PET/CT imaging will be performed on the enrolled patients. |
FAP-targeting PET/CT imaging will be performed on the enrolled patients. |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Pathological type
大体时间:1 week after enrollment
|
pathological type (e.g., sclerosing IgA nephropathy) |
1 week after enrollment
|
|
Baseline serum creatinine (μmol/L)
大体时间:1 month before enrollment and 1 month after enrollment
|
laboratory results |
1 month before enrollment and 1 month after enrollment
|
|
Baseline 24-hour urinary protein (g/24h)
大体时间:1 month before enrollment and 1 month after enrollment
|
laboratory results |
1 month before enrollment and 1 month after enrollment
|
|
Quantified renal pathological involvement.
大体时间:1 week after enrollment
|
Based on kidney biopsy sections, interstitial atrophy, interstitial inflammatory infiltration, and tubular fibrosis will be quantified. |
1 week after enrollment
|
|
Pathological MESTC score
大体时间:1 week after enrollment
|
MESTC score (0-2, for IgA nephropathy patients) |
1 week after enrollment
|
次要结果测量
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Follow-up serum creatinine (μmol/L)
大体时间:From 1 month after enrollment to 60 month after enrollment
|
laboratory results |
From 1 month after enrollment to 60 month after enrollment
|
|
Proteinuria remisssion
大体时间:From 1 month after enrollment to 60 month after enrollment
|
For IgA nephropathy (IgAN) patients with baseline urinary total protein (UTP) exceeding 0.5 g/24h, a reduction of UTP to below 0.5 g/24h without recurrence within 4 weeks was considered proteinuria remission. |
From 1 month after enrollment to 60 month after enrollment
|
|
Acute kidney disease remission
大体时间:Within 3 month after enrollment
|
For IgAN patients with AKD, AKD remission was defined as a reduction in SCr to below 75% of the peak value within 90 days after imaging. Remission was classified as complete if the difference between the last recorded SCr and baseline SCr was ≤26.5 μmol/L; otherwise, it was classified as partial. Baseline SCr was defined as the lowest value recorded within 90 days prior to hospital admission. If unavailable, the lowest SCr value within 90 days after admission was used as the baseline. |
Within 3 month after enrollment
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.